

Enhanced Chondrogenesis of Induced Pluripotent Stem Cells From Patients With Neonatal-Onset Multisystem Inflammatory Disease Occurs via the Caspase 1–Independent cAMP/Protein Kinase A/CREB Pathway

Koji Yokoyama,¹ Makoto Ikeya,¹ Katsutsugu Umeda,¹ Hirotugu Oda,² Seishiro Nodomi,¹ Akira Nasu,¹ Yoshihisa Matsumoto,³ Kazushi Izawa,¹ Kazuhiko Horigome,⁴ Toshimasa Kusaka,¹ Takayuki Tanaka,¹ Megumu K. Saito,¹ Takahiro Yasumi,¹ Ryuta Nishikomori,¹ Osamu Ohara,⁵ Naoki Nakayama,⁶ Tatsutoshi Nakahata,¹ Toshio Heike,¹ and Junya Toguchida¹

Objective. Neonatal-onset multisystem inflammatory disease (NOMID) is a dominantly inherited auto-inflammatory disease caused by NLRP3 mutations. NOMID pathophysiology is explained by the NLRP3 inflammasome, which produces interleukin-1 β (IL-1 β). However, epiphyseal overgrowth in NOMID is resistant

to anti-IL-1 therapy and may therefore occur independently of the NLRP3 inflammasome. This study was undertaken to investigate the effect of mutated NLRP3 on chondrocytes using induced pluripotent stem cells (iPSCs) from patients with NOMID.

Methods. We established isogenic iPSCs with wild-type or mutant NLRP3 from 2 NOMID patients with NLRP3 somatic mosaicism. The iPSCs were differentiated into chondrocytes in vitro and in vivo. The phenotypes of chondrocytes with wild-type and mutant NLRP3 were compared, particularly the size of the chondrocyte tissue produced.

Results. Mutant iPSCs produced larger chondrocyte masses than wild-type iPSCs owing to glycosaminoglycan overproduction, which correlated with increased expression of the chondrocyte master regulator SOX9. In addition, in vivo transplantation of mutant cartilaginous pellets into immunodeficient mice caused disorganized endochondral ossification. Enhanced chondrogenesis was independent of caspase 1 and IL-1, and thus the NLRP3 inflammasome. Investigation of the human SOX9 promoter in chondroprogenitor cells revealed that the CREB/ATF-binding site was critical for SOX9 overexpression caused by mutated NLRP3. This was supported by increased levels of cAMP and phosphorylated CREB in mutant chondroprogenitor cells.

Conclusion. Our findings indicate that the intrinsic hyperplastic capacity of NOMID chondrocytes is dependent on the cAMP/PKA/CREB pathway, independent of the NLRP3 inflammasome.

Supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Health, Labor, and Welfare, the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT Leading Project for Realization of Regenerative Medicine), the Japanese Science and Technology Agency (Program for Intractable Diseases Research Utilizing Disease-Specific Induced Pluripotent Stem Cells), the Secom Science and Technology Foundation, and the Induced Pluripotent Stem Cell Research Fund.

¹Koji Yokoyama, MD, Makoto Ikeya, PhD, Katsutsugu Umeda, MD, PhD, Seishiro Nodomi, MD, Akira Nasu, MD, PhD, Kazushi Izawa, MD, PhD, Toshimasa Kusaka, PhD, Takayuki Tanaka, MD, PhD, Megumu K. Saito, MD, PhD, Takahiro Yasumi, MD, PhD, Ryuta Nishikomori, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Toshio Heike, MD, PhD, Junya Toguchida, MD, PhD: Kyoto University, Kyoto, Japan; ²Hirotugu Oda, MD: Kyoto University, Kyoto, Japan, and RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; ³Yoshihisa Matsumoto, MD, PhD: Kyoto University, Kyoto, Japan, and Nagoya City University, Nagoya, Japan; ⁴Kazuhiko Horigome, PhD: Kyoto University, Kyoto, Japan, and Dainippon Sumitomo Pharma, Osaka, Japan; ⁵Osamu Ohara, PhD: RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, and Kazusa DNA Research Institute, Kisarazu, Japan; ⁶Naoki Nakayama, PhD: University of Texas Health Science Center at Houston.

Address correspondence to Ryuta Nishikomori, MD, PhD, Department of Pediatrics, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan (e-mail: rnishiko@kuhp.kyoto-u.ac.jp); or to Junya Toguchida, MD, PhD, Department of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan (e-mail: togjun@frontier.kyoto-u.ac.jp).

Submitted for publication February 10, 2014; accepted in revised form October 7, 2014.

Systemic autoinflammatory syndromes are caused by defects in the innate immune system, especially pattern-recognition receptors, which result in uncontrolled inflammatory responses (1). Neonatal-onset multisystem inflammatory disease (NOMID) is a systemic autoinflammatory disease caused by NLRP3 mutation (2). The clinical features of NOMID include neonatal-onset persistent inflammation, urticarial rash, chronic aseptic meningitis, and arthropathy characterized by tumor-like expansive lesions in epiphyseal portions of long bones (3). NLRP3 is mainly expressed in hematopoietic cells, especially monocyte/macrophages, and in chondrocytes (4). In monocyte/macrophages, once NLRP3 is activated by its ligand, a multiprotein complex called the NLRP3 inflammasome forms, resulting in the activation of caspase 1, which cleaves pro-interleukin-1 β (IL-1 β) into active IL-1 β (5–8).

The molecular mechanism by which NOMID-associated NLRP3 mutations lead to the activation of the NLRP3 inflammasome has not been fully elucidated. However, it is hypothesized that mutated NLRP3 can trigger the formation of the NLRP3 inflammasome independently of ligand binding, which causes dysregulated IL-1 β secretion and uncontrolled multisystem inflammation. This hypothesis is supported by the fact that a targeted therapy against IL-1 β effectively controls systemic inflammation in NOMID (9–11). However, epiphyseal overgrowth in NOMID is resistant to anti-IL-1 therapy (12).

Sequential radiologic imaging and histologic analyses of tissue biopsy specimens suggest that the main pathophysiology of NOMID arthropathy is not inflammation but disorganization of cartilage cell columns that leads to tumor-like expansive lesions (13). These clinical and pathologic findings suggest that mutant NLRP3 induces epiphyseal overgrowth in NOMID via mechanisms unrelated to the NLRP3 inflammasome. However, the function of NLRP3 in chondrocytes has not been elucidated, let alone the mechanism underlying epiphyseal overgrowth in NOMID.

Cartilage is a flexible connective tissue in the skeletal system and consists of chondrocytes and extracellular matrix (ECM). The growth plate consists of a column of chondrocytes that separate the epiphysis and metaphysis of a long bone. The primary function of these chondrocytes is to provide a cartilage template on which bone can form through endochondral ossification. In the growth plate, maturing chondrocytes are organized into resting, proliferating, prehypertrophic, and hypertrophic zones. Growth factor signaling stimulates mesenchymal progenitor cells in the resting zone to

proliferate, upon which they move to the proliferating zone. These cells subsequently produce cartilage-specific ECM consisting of type II collagen and type XI collagens, and proteoglycans, such as aggrecan and cartilage oligomeric matrix protein. These cells then exit the cell cycle, differentiate, become hypertrophic, produce type X collagen and matrix metalloproteinases, and finally undergo apoptosis. The remaining cartilaginous matrix is mineralized and provides a scaffold on which bone can form (14,15).

It is difficult to obtain bone tissues from NOMID patients due to ethical reasons. Moreover, osteochondrogenic progenitor cells often cannot be obtained from postnatal human tissues in sufficient quantities, while acquiring such cells in sufficient quantities from human fetuses or embryos is ethically challenging. Furthermore, although a mass-like lesion called a “spike” is observed in mouse models of NOMID arthropathy (16), these models do not recapitulate the epiphyseal overgrowth observed in NOMID. These issues have prevented elucidation of the pathophysiologic mechanism underlying epiphyseal overgrowth in NOMID. In this study, we applied a newly developed chondrocyte differentiation system to induced pluripotent stem cells (iPSCs) derived from NOMID patients. This system allowed chondrocytes to be obtained in sufficient quantities to directly study the effect of mutated NLRP3 on chondrocyte phenotypes, focusing on the involvement of the NLRP3 inflammasome and the master regulator of chondrocyte differentiation, SOX9.

MATERIALS AND METHODS

Cell culture. Undifferentiated iPSCs from 2 NOMID patients with NLRP3 somatic mosaicism (p.Tyr570Cys and p.Gly307Ser) were established as previously described (17). From each patient, at least 3 clones of iPSCs with mutant or wild-type NLRP3 were established. In all experiments, mutant and wild-type isogenic cells were compared (3). Details of the procedure for culture of undifferentiated iPSCs and chondrogenic differentiation are available from the author upon request. The iPSCs were seeded onto a Matrigel (Becton Dickinson)-coated dish, cultured in mTeSR medium (Stem-Cell Technologies) for 9 days, and then transferred to initial differentiation medium. This medium was changed once on day 3. On day 6, a single-cell suspension was prepared with 0.05% trypsin-EDTA. These cells were plated onto fibronectin-coated dishes, cultured in chondroprogenitor medium, and passaged every 3 days. We called these cells chondroprogenitor cells. For chondrogenesis, chondroprogenitor cells that had been passaged 3–5 times were used (Figure 1A).

Chondrogenesis assay. Serum-free chondrogenic medium has been described previously (18). Two-dimensional




Figure 1. Successful differentiation of chondrocytes from induced pluripotent stem cells (iPSCs) with wild-type (WT) or mutant NLRP3 obtained from a patient with neonatal-onset multisystem inflammatory disease. **A**, Schematic representation of the culture conditions used to differentiate chondrocytes from iPSCs. **B**, Immunohistochemical staining of chondrocytes differentiated from iPSCs. Alcian blue staining of the 2-dimensional (2-D) micromass culture, Alcian blue staining of the 3-dimensional (3-D) pellet culture, higher-magnification images of Alcian blue staining of the 3-D pellet culture, anti-type II collagen (anti-COL2) antibody staining of the 3-D pellet culture, and anti-type II collagen antibody staining of mouse bladder (negative control) are shown. White bars = 2.0 mm; black bars = 0.2 mm. **C**, Quantitative analysis of the sizes of chondrocyte tissue masses in 2-D micromass cultures and 3-D pellet cultures. **D**, Cartilage-specific gene expression in 3-D pellet cultures. Expression of mRNA for each gene is shown relative to that in human cartilage (for *SOX9*, *COL2A1*, *ACAN*, and *COMP*) or the osteosarcoma cell line ANOS (for *IHH*, *MMP13*, *COL10A1*, and *VEGFA*), which were both set at 1. Bars in **C** and **D** show the mean $\pm$ SEM of 3 independent clones, from which duplicate measurements (**C**) or triplicate measurements (**D**) were obtained. Data are representative of 3 independent experiments and were obtained using iPSCs from patient 1 (p.Tyr570Cys); similar data were obtained using iPSCs from patient 2 (p.Gly307Ser). * = $P < 0.05$. ES = embryonic stem; PDGF-BB = platelet-derived growth factor BB; BMP-4 = bone morphogenetic protein 4; TGF β 3 = transforming growth factor β 3; bFGF = basic fibroblast growth factor.

(2-D) micromass culture was performed by spotting a 5- μ l droplet of chondrogenitor cells (1.5×10^5) onto the well of a fibronectin-coated 24-well plate in serum-free chondrogenic medium supplemented with 40 ng/ml of platelet-derived growth factor BB (PDGF-BB; R&D Systems) and 1% fetal calf serum. The medium was changed every 3 days. Beginning on day 21, 10 ng/ml of transforming growth factor β 3 (TGF β 3; R&D Systems) was added, and beginning on day 25, 40 ng/ml

of PDGF-BB was replaced with 50 ng/ml of bone morphogenetic protein 4 (Wako). For 3-dimensional (3-D) pellet cultures, chondrogenitor cells were passaged once in chondrogenitor medium containing 5 ng/ml of basic fibroblast growth factor and 10 ng/ml of TGF β 3, and then cultured for 3 days. Aliquots of 2.5×10^5 cells were centrifuged to form pellets, which were cultured in 0.5 ml of serum-free chondrogenic medium supplemented with specific factors as outlined

above. Fixation and staining of the 2-D micromass and 3-D pellet cultures were performed as previously described (18). Glycosaminoglycan (GAG) and sulfated proteoglycan levels and DNA content were quantified as previously described (19).

Chondrogenesis in vivo. Cartilaginous pellets formed by 3-D cell pellet cultures over 20 days were wrapped in a 0.5 cm × 1 cm Gelfoam (Pfizer) and transplanted beneath the dorsal skin of immunodeficient NOD/Shi-scid, IL-2Rγ(null) (NOG) mice. Four weeks later, cartilage and bone particles were harvested, fixed with paraformaldehyde for 24 hours, embedded in plastic, sectioned, and stained with hematoxylin and eosin (H&E), von Kossa, or Alcian blue, as previously reported (18).

Enzyme-linked immunosorbent assay (ELISA) and Western blotting. The concentration of cAMP was measured using an ELISA (Cell Signaling Technology). Antibodies against CREB, phosphorylated CREB (Cell Signaling), and β-actin (Santa Cruz Biotechnology) were used for Western blotting, as previously described (20).

Gene expression profiling. Total RNA was extracted and reverse-transcribed to cDNA using Superscript III reverse transcriptase (Invitrogen) according to the manufacturer's protocol. Quantitative reverse transcriptase–polymerase chain reaction was performed as previously described (19). The expression levels of each gene from duplicate or triplicate reactions were normalized against the level of the *BACT* transcript and are shown relative to their expression in the osteosarcoma cell line ANOS (21) or a human articular cartilage sample.

Reporter assay for the human SOX9 promoter. To measure the activity of the human *SOX9* promoter in chondroprogenitor cells, the 5'-untranslated region (5'-UTR) of the human *SOX9* gene (−927 to +84 bp) was inserted into a pGL3-luciferase reporter plasmid (Promega), as previously described (22). Site-directed mutagenesis of the known transcription factor-binding sites of the human *SOX9* promoter was performed as previously described (23). The residue was mutated to the nucleotide that was least likely to be at this position, based on consensus sequences in the JASPAR transcription database (24). Sequence information is provided in Supplementary Figure 1, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.38912/abstract>. Chondroprogenitor cells were plated at a density of 50,000 cells/well in 6-well plates, transfected with 2 μg of DNA/well using the FuGene 6 transfection reagent, and harvested 24 hours after transfection. Luciferase activity was measured as previously described (23). Additionally, 10 μM forskolin (Sigma) and 10 μM SQ22536 (Sigma) was used to activate and inhibit adenylate cyclase, respectively.

Ethics approval. This study was approved by the ethics committee of Kyoto University and was performed in accordance with the Declaration of Helsinki. A sample of human articular cartilage was obtained from a patient who underwent knee surgery and provided informed consent that the sample could be used for research purposes.

Statistical analysis. Data were analyzed using Student's *t*-test. *P* values less than 0.05 were considered significant.

RESULTS

Production of a large cartilaginous mass by chondrocytes differentiated from iPSCs with mutated NLRP3. To investigate the pathophysiology of NOMID arthropathy, we attempted to recapitulate this phenotype by using chondrocytes that were differentiated from iPSCs derived from patients with NOMID. We obtained iPSCs from 2 NOMID patients with arthropathy who had *NLRP3* somatic mosaicism, as previously described (17). We established isogenic iPSC clones that had mutated or wild-type *NLRP3*, which allowed us to examine the effects of *NLRP3* mutations in the same genetic background (25,26).

To produce chondrocytes from these iPSCs, we used a protocol in which chondrocytes are obtained from cells of neural crest character (details are available from the author upon request) (Figure 1A). We performed 2 chondrogenic assays, a 2-D micromass culture assay and a 3-D pellet assay. The former is suitable for experiments with exogenous inhibitors or activators, whereas the latter generates more mature chondrocytes for in vivo transplantation assay. First, we confirmed the phenotype of cartilage samples by performing Alcian blue staining, which labels ECM excreted by chondrocytes, and immunostaining for type II collagen, which is specifically expressed in chondrocytes (Figure 1B). After culture in chondrogenic medium, cells derived from wild-type and mutant iPSCs were positive for Alcian blue and type II collagen, which confirmed that the iPSCs had successfully differentiated into chondrocytes. Importantly, the 2-D micromass and 3-D pellet samples derived from mutant iPSCs were significantly larger than those derived from wild-type iPSCs, up to day 74 of culture (Figures 1B and C).

Next, we examined the expression of mRNA for cartilage-related genes expressed in proliferating chondrocytes (early markers; *SOX9*, *COL2A1*, *ACAN*, and *COMP*) and those expressed in hypertrophic chondrocytes (late markers; *IHH*, *MMP13*, *COL10A1*, and *VEGFA*) in samples obtained by the method described above (Figure 1D). These genes were expressed in 3-D pellet samples obtained from mutant and wild-type iPSCs, further indicating that chondrocyte differentiation was successful and that 3-D pellets contained chondrocytes at various differentiation stages. The expression levels of both early and late chondrogenic markers were significantly higher in mutant samples than in wild-type samples (Figure 1D). Taken together, these data show that chondrocytes were successfully differentiated in




Figure 2. Formation of large cartilaginous masses by mutant iPSCs from patients with neonatal-onset multisystem inflammatory disease is due to the overproduction of extracellular matrix and not due to increased cell proliferation. **A**, Growth curves of chondroprogenitor cells differentiated from mutant and wild-type iPSCs. Values are the mean $\pm$ SEM of 3 independent clones, from which duplicate measurements were obtained. **B** and **C**, DNA concentration, glycosaminoglycan (GAG) concentration, and the ratio of GAG concentration to DNA concentration in 2-D micromass (**B**) and 3-D pellet (**C**) cultures. Bars show the mean $\pm$ SEM of 3 independent clones, from which triplicate (**B**) or duplicate (**C**) measurements were obtained. Data are representative of 3 independent experiments with consistent results. * = $P < 0.05$. See Figure 1 for other definitions.

vitro from iPSCs derived from NOMID patients, and that chondrocytes differentiated from iPSCs with mutant *NLRP3* produce large cartilaginous masses in vitro. They also demonstrate that the entire chondrocyte differentiation process, from precursors to late chondrocytes, is enhanced in mutant cells compared to wild-type cells.

The production of large cartilaginous masses by mutant iPSCs is due to ECM overproduction, not to increased cell proliferation. We next sought to determine what causes the chondrocyte masses derived from mutant iPSCs to be larger than those derived from wild-type iPSCs. First, we analyzed the proliferation potential of chondroprogenitor cells. Population doubling time did not significantly differ between mutant and wild-type chondroprogenitor cells up to 15 passages, after which the cells stopped proliferating (Figure 2A). Next, we determined the number of differentiated chondrocytes by analyzing DNA content and GAG produc-

tion, which is a major cartilaginous ECM component. In 2-D micromass and 3-D pellet cultures, the DNA content in differentiated chondrocyte tissue derived from mutant and wild-type iPSCs did not significantly differ. This suggests that a similar number of chondrocytes were produced from mutant and wild-type iPSCs. In contrast, chondrocytes derived from mutant iPSCs produced more GAG than those derived from wild-type iPSCs in 2-D micromass culture (Figure 2B) and 3-D pellet culture (Figure 2C). These data indicate that the larger amount of chondrocyte tissue produced from mutant iPSCs is not due to an increased number of chondrocytes, but to an increased amount of cartilaginous ECM produced per cell.

In vivo differentiation of chondrocytes from mutant iPSCs reveals dysregulated endochondral ossification. Radiologic examination of affected long bones in NOMID patients shows enlargement of the epiphysis




Figure 3. In vivo maturation of 3-D cell pellets derived from mutant or wild-type iPSCs from patients with neonatal-onset multisystem inflammatory disease. **A**, Images of 3-D cell pellets derived from mutant or wild-type iPSCs following transplantation into immunodeficient mice. Gross appearance, hematoxylin and eosin (H&E) staining, Alcian blue staining, von Kossa staining, and higher-magnification images of von Kossa staining are shown. Red circles indicate bone or cartilage pellets in gel form. White bars = 2.0 mm; black bars = 0.2 mm. Results shown were obtained using iPSCs from patient 1; similar results were obtained using iPSCs from patient 2. **B**, Quantitative analysis of the size of pellets when they were transplanted (day 38) and harvested (day 66). Bars show the mean $\pm$ SEM of 3 independent clones, from which duplicate measurements were obtained. Data are representative of 3 independent experiments. * = $P < 0.05$. See Figure 1 for other definitions.

with abnormal ossification. The in vitro differentiation system did not induce chondrocyte calcification, probably due to the lack of cell components or factors necessary for the final differentiation step. Therefore, we used an in vivo differentiation system as a model for endochondral ossification, in which immature 3-D pellet samples were transplanted into NOG mice. The transplanted cartilage mass was vascularized in vivo (Figure 3A). Mutant pellets were larger than wild-type pellets, both at transplantation and harvesting, and this size difference increased during in vivo differentiation (Figure 3B). Following von Kossa staining, which detects calcium deposits, calcification was detected in both wild-type and mutant pellets (Figure 3A). Interestingly, Alcian blue staining revealed that mutant pellets contained more residual cartilage components than wild-

type pellets. In addition, calcified areas were scattered throughout mutant pellets, whereas they were localized in specific regions and were clearly separated from Alcian blue-positive areas in wild-type pellets. Taken together, these data indicate that in our in vivo model, chondrocyte tissue differentiated from mutant iPSCs grows larger and exhibits disorganized ossification compared to chondrocyte tissue differentiated from wild-type iPSCs.

The enhanced chondrogenesis of mutant iPSCs is independent of the NLRP3 inflammasome. The inflammatory phenotype of NOMID is caused by gain-of-function NLRP3 mutations, leading to activation of the NLRP3 inflammasome (27). Therefore, we examined the involvement of the NLRP3 inflammasome in the formation of cartilaginous masses. First, we analyzed the




Figure 4. NLRP3 inflammasome-independent enhanced chondrogenesis of mutant iPSCs from patients with neonatal-onset multisystem inflammatory disease. Wild-type and mutant iPSCs were differentiated into chondrocytes in 2-D micromass cultures, and the caspase 1 inhibitor Ac-YVAD-CHO (YVAD; 10 μ M) or human recombinant interleukin-1 receptor antagonist (IL-1Ra; 1 μ g/ml) was added to the cultures. Control cultures were incubated with DMSO or phosphate buffered saline (PBS) containing bovine serum albumin (BSA). **A**, Representative 2-D micromass cultures treated with YVAD or DMSO as control (left) or with IL-1Ra or PBS/BSA as control (right). **B**, Diameter of the micromass. **C**, *SOX9* expression in chondrocytes derived from wild-type and mutant iPSCs and treated with YVAD or IL-1Ra. Expression levels are shown relative to those in ANOS cells (set at 1). **D**, DNA concentration, glycosaminoglycan (GAG) concentration, and the ratio of GAG concentration to DNA concentration in chondrocytes derived from wild-type or mutant iPSCs and treated with YVAD or IL-1Ra. Bars show the mean $\pm$ SEM of 3 independent clones from which triplicate measurements were obtained. Data are representative of 3 independent experiments. Data shown were obtained using iPSCs from patient 1; similar results were obtained using iPSCs from patient 2. * = $P < 0.05$. See Figure 1 for other definitions.

expression of the NLRP3 inflammasome components in 2-D cartilage samples. Mutant and wild-type cartilage samples both expressed NLRP3, but did not express ASC, pro-caspase 1, or pro-IL-1 β by Western blotting (data not shown). This suggests that the formation of large cartilaginous masses by mutant chondrocytes occurs independently of the NLRP3 inflammasome.

To confirm that chondrogenesis of mutant iPSCs is enhanced independently of the NLRP3 inflammasome, we used inhibitors of components of the

NLRP3 inflammasome, namely, Ac-YVAD-CHO, which inhibits caspase 1, and recombinant human IL-1 receptor antagonist (IL-1Ra), which antagonizes IL-1. Neither Ac-YVAD-CHO (10 μ M) treatment nor recombinant human IL-1Ra (1 μ g/ml) treatment during 2-D micromass culture prevented the formation of large cartilaginous masses (Figures 4A and B), *SOX9* up-regulation (Figure 4C), or overproduction of GAG (Figure 4D) by chondrocytes derived from mutant iPSCs. The same was true when samples were treated




Figure 5. Up-regulation of the expression of *SOX9* and *COL2A1* in chondrocytes with mutated *NLRP3* during the chondroprogenitor cell stage. Expression of *SOX9*, *COL2A1*, *ACAN*, *COMP*, and *NLRP3* in each clone was measured in triplicate from day -9 to day 15 of chondrocyte differentiation of iPSCs from patients with neonatal-onset multisystem inflammatory disease with wild-type or mutant *NLRP3*. Expression levels of *SOX9*, *COL2A1*, *ACAN*, and *COMP* are shown relative to those in ANOS cells (set at 1), and the expression level of *NLRP3* is shown relative to that in peripheral blood mononuclear cells (PBMCs; set at 1). Bars show the mean $\pm$ SEM of 3 independent clones. Data are representative of 3 independent experiments with consistent results and were obtained using iPSCs from patient 1; similar results were obtained using iPSCs from patient 2. * = $P < 0.05$. See Figure 1 for other definitions.

with higher concentrations of these inhibitors (up to 1,000-fold higher) (data not shown). Taken together, these data strongly indicate that the enhanced chondrogenesis of mutant iPSCs is independent of caspase 1 and IL-1, and thus the *NLRP3* inflammasome.

Correlation of the up-regulation of *NLRP3* with the up-regulation of *SOX9* in chondroprogenitor cells. To dissect the mechanism underlying the enhanced chondrogenesis of mutant iPSCs, we analyzed the time course of chondrocyte-specific gene expression in chondroprogenitor cells (Figure 5). Expression of *SOX9*, *COL2A1*, and *NLRP3* started to be up-regulated in chondroprogenitor cells on day 6. Importantly, on day 15, *SOX9* and *COL2A1* were up-regulated more in mutant chondroprogenitor cells than in wild-type chondroprogenitor cells, whereas *NLRP3* was up-regulated similarly in both types of cells (Figure 5). In contrast, at this time point, the other chondrocyte-specific markers *ACAN* and *COMP* were not expressed in either type of cell (Figure 5). Thus, differential up-regulation of *SOX9* in chondroprogenitor cells correlated with the up-regulation of *NLRP3* and preceded the up-regulation of *COMP* and *ACAN*.

Critical role of the CREB/ATF-binding site of the *SOX9* promoter in mutated *NLRP3*-dependent enhancement of *SOX9* expression. Next, we focused on *SOX9* because it was up-regulated together with *NLRP3*, and this preceded the up-regulation of other chondrocyte-specific markers. We analyzed the activity of the human *SOX9* promoter in chondroprogenitor cells in which the level of *SOX9* mRNA was increased. We created a luciferase reporter construct containing the 5'-UTR of human *SOX9*, which encompasses -927 to +84 bp of the transcription start site. This fragment has basal promoter activity and putative binding sites for 5 transcription factors, namely, NF-AT, activator protein 1 (AP-1), NF- κ B, Sp1, and CREB/ATF (see Supplementary Figure 1, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.38912/abstract>). This fragment showed no promoter activity in the monocytic cell line THP-1 or the erythroleukemic cell line K562, which do not express endogenous *SOX9* (data not shown). Importantly, human *SOX9* promoter activity was higher in mutant chondroprogenitor cells than in wild-type chondroprogenitor cells (Figure 6A). To identify the element of the human *SOX9*




Figure 6. *SOX9* up-regulation in chondrocytes derived from iPSCs from patients with neonatal-onset multisystem inflammatory disease with mutant NLRP3 is dependent on the cAMP/protein kinase A (PKA)/CREB pathway. **A**, *SOX9* promoter activity in wild-type and mutant chondroprogenitor cells after the introduction of mutations into its transcription factor binding sites. **B**, *SOX9* promoter activity and expression in wild-type and mutant chondroprogenitor cells treated with SQ22536 or forskolin. **C**, Effects of SQ22536 and forskolin on 3-D pellets of mutant and wild-type cells. Both reagents were used at a concentration of 10 μ M. Bars = 2.0 mm. **D**, Increased activity of the cAMP/PKA/CREB pathway in mutant chondroprogenitor cells compared to wild-type chondroprogenitor cells, as demonstrated by cAMP concentration in wild-type and mutant iPSCs (day 0) and chondroprogenitor cells (day 15 and day 36), and Western blot analysis of phosphorylated CREB in wild-type (WT1–3) and mutant (MT1–3) chondroprogenitor cells. **E**, Schematic diagram summarizing the molecular mechanism elucidated in this study. Bars in **A–D** show the mean $\pm$ SEM of 3 independent clones from which triplicate (**A**, **B**, and **D**) or duplicate (**C**) measurements were obtained. Data are representative of 2 independent experiments with consistent results and were obtained using iPSCs from patient 1; similar results were obtained using iPSCs from patient 2. * = $P < 0.05$. See Figure 1 for other definitions.

promoter region that responds in a mutated NLRP3-dependent manner, we performed site-directed mutagenesis of the sites of this promoter that bind the transcription factors NF-AT, AP-1, NF- κ B, Sp1, and CREB/ATF (Supplementary Figure 1). Among the reporters with these mutations, the reporter that harbored a mutation in the CREB/ATF-binding site showed the least up-regulation of *SOX9* promoter activity in mutant cells (Figure 6A and Supplementary Figure 1). Thus, we speculate that the CREB/ATF-binding site is critical for

activation of the human *SOX9* promoter in a mutated NLRP3-dependent manner.

Critical role of the cAMP/PKA/CREB pathway in *SOX9* up-regulation caused by mutated NLRP3. To further explore the association between mutated NLRP3 and the cAMP/PKA/CREB pathway, we examined the effect of an adenylate cyclase activator and inhibitor (forskolin and SQ22536, respectively) on the activity of the human *SOX9* promoter and *SOX9* mRNA expression (Figure 6B). Among mutant chondroprogenitor

cells, *SOX9* promoter activity was 2.3-fold higher in forskolin-treated cells than in vehicle-treated cells, whereas *SOX9* promoter activity was 2-fold lower in SQ22536-treated cells than in vehicle-treated cells (Figure 6B). Similar effects were observed in wild-type chondroprogenitor cells, although they were less pronounced. These data correlated well with the effects of forskolin and SQ22536 on *SOX9* mRNA expression. We also examined the effects of forskolin and SQ22536 on 3-D chondrocyte pellet formation (Figure 6C). Compared to pellets of vehicle-treated mutant cells, pellets of mutant cells treated with forskolin and SQ22536 were 2.0-fold larger and 2.1-fold smaller, respectively. Similar effects were observed in wild-type cells, although they were less pronounced. These data clearly indicate that up-regulation of *SOX9* following activation of adenylate cyclase is involved in the enhanced chondrogenesis of mutant iPSCs.

We next measured the cAMP concentration to demonstrate that the activity of adenylate cyclase is increased in mutant chondroprogenitor cells. The concentration of cAMP was 4-fold higher in mutant chondroprogenitor cells than in wild-type chondroprogenitor cells on days 15 and 36 (Figure 6D). By contrast, the concentration of cAMP was similar in mutant and wild-type iPSCs, in which NLRP3 expression was low.

Finally, we examined the level of phosphorylated CREB in chondroprogenitor cells. CREB is phosphorylated by cAMP-activated PKA. According to Western blot analysis, the level of phosphorylated CREB was higher in mutant chondroprogenitor cells than in wild-type chondroprogenitor cells on days 15 and 36 (Figure 6D). Taken together, these data indicate that the cAMP/PKA/CREB pathway plays an important role in the up-regulation of *SOX9*, and therefore enhanced chondrogenesis, in chondroprogenitor cells with mutant NLRP3 (Figure 6E).

DISCUSSION

Disease-specific iPSCs have been used extensively to investigate the pathogenesis of diseases and to discover novel drugs. This approach is particularly useful to study rare diseases because tissues are often difficult to obtain from patients with such diseases. In this study, we used disease-specific iPSCs to study NOMID. Using this approach, we produced chondrocyte tissues with mutant and wild-type NLRP3, and revealed a previously unidentified connection between the inflammasome-associated molecule NLRP3 and the master regulator of chondrocyte differentiation *SOX9*.

SOX9 was up-regulated during the differentiation of iPSCs into chondrocytes, and this was particularly pronounced in mutant iPSCs. During cartilage development, *SOX9* is highly expressed in immature chondrocytes and is required for the condensation and differentiation of mesenchymal cells. During the early stages of chondrogenesis, *SOX9* activates the transcription of many cartilage-specific ECM genes, including *COL2A1*, *ACAN*, and *COMP*, by directly interacting with *SOX5* and *SOX6* (28,29). Overexpression of *SOX9* in chondrocytes using a recombinant adeno-associated virus significantly increases the synthesis of major ECM components in chondrocytes, without affecting their proliferation, in vivo and in vitro (30,31). In addition, retroviral transduction of *SOX9* increases ECM production in human chondrocytes in vitro (32). These data correlate well with our observation that *SOX9* overexpression driven by mutated NLRP3 caused overproduction of ECM, but did not increase chondrocyte proliferation.

It remains to be determined how enhanced expression of *SOX9* in chondrocytes leads to epiphyseal overgrowth in NOMID patients. Conditional transgenic mice have been used to show that overexpression of *SOX9* in *COL2A1*-positive cells inhibits terminal differentiation of hypertrophic chondrocytes and endochondral bone formation (29). Although we have not directly confirmed the expression level of *SOX9* in samples derived from NOMID patients, this previous study might help to link the findings of the present study with the clinical phenotype of NOMID patients.

We identified the cAMP/PKA/CREB pathway as being critical for the up-regulation of *SOX9* mRNA in a mutant NLRP3-dependent manner. cAMP is an intracellular second messenger that is involved in a variety of cellular processes (33). cAMP/PKA/CREB signaling is crucial in chondrogenesis, and synergism between cAMP and *SOX9* is particularly important (34–36). Cotransfection of CREB binding protein (CBP) and p300 increases *SOX9* activity (35). PKA phosphorylates *SOX9* and thereby increases *SOX9* activity, which results in the up-regulation of the *COL2A1* promoter through the interaction between CBP and *SOX9* (34). In addition, the PKA inhibitor H89 blocks chondrogenesis in the chick limb bud (36). These data support the idea that cAMP/PKA/CREB signaling up-regulates *SOX9* to enhance chondrogenesis.

Using stromal cells established from a tumor-like lesion in a NOMID patient, Almeida et al (37) demonstrated that activation of the cAMP/PKA/CREB pathway leads to caspase 1 activation, release of IL-1 β , and

consequently the proliferation of bone stromal cells. This suggests that bone lesions in NOMID are caused in an NLRP3 inflammasome-dependent manner. One explanation for the discrepancy between their data and ours is that no disease-causing NLRP3 mutation was identified in the patient in that previous study; therefore, an unknown genetic alteration may have caused the NOMID phenotype. Another explanation is that different cell types were analyzed in the two studies. The previous study analyzed bone stromal cells established from a tumor-like lesion that might have been a heterogeneous population, while we focused on a single cell type, namely, chondrocytes.

The lack of environmental factors and interactions with other cell populations in our model might have eliminated some contributions of the NLRP3 inflammasome and IL-1 β pathway that occur in NOMID patients. Furthermore, our observations relied on an artificial differentiation system in which iPSCs were first differentiated into cells of neural crest character and then into chondrocytes by culture in the presence of various exogenous factors. Abnormal epiphyseal growth is specifically observed around the knee joints of NOMID patients; therefore, additional events might be required to trigger abnormal chondrocyte proliferation *in vivo*. It is also possible that specific factors produced by surrounding cells in unaffected joints prevent mutant chondrocytes from manifesting their phenotype. Further analyses of patients or patient-derived samples would provide a better understanding of the pathophysiology of arthropathy in NOMID.

The interaction between cAMP and NLRP3 has been studied in monocyte/macrophages, in which the NLRP3 inflammasome is activated following binding of extracellular Ca²⁺ to Ca²⁺-sensing receptors (CaSRs) (38,39). One study reported that an increase in extracellular Ca²⁺ is detected by CaSRs, which leads to phospholipase C activation and subsequently the release of Ca²⁺ from the endoplasmic reticulum and down-regulation of cAMP. cAMP binds directly to NLRP3 and inhibits assembly of the NLRP3 inflammasome. Therefore, this decrease in the level of intracellular cAMP relieves this inhibition and thereby induces activation of the NLRP3 inflammasome (38). On the other hand, another study reported that an increase in the extracellular Ca²⁺ concentration induces an increase in the intracellular Ca²⁺ concentration, thereby leading to activation of the NLRP3 inflammasome, and this mechanism requires the CaSRs GPRC6A and CaSR, but not the down-regulation of cAMP (39). Thus, the effects of

cAMP on the NLRP3 inflammasome in monocyte/macrophages remain a subject of controversy.

In the chondrocyte differentiation system used in the present study, mutated NLRP3 caused SOX9 overexpression via the cAMP/PKA/CREB pathway, which is at odds with the relationship between cAMP and activation of the NLRP3 inflammasome in monocyte/macrophages. This discrepancy might be explained by the absence of other NLRP3 inflammasome components, such as ASC and procaspase 1, in the chondrocytes generated in the present study. Further analysis is needed to determine why cAMP/PKA/CREB signaling elicits different effects on mutated NLRP3 in chondrocytes and monocyte/macrophages, as well as how intracellular cAMP is up-regulated in chondrocytes derived from mutant iPSCs.

There have been many reports on the differentiation of chondrocytes from embryonic stem cells (ESCs) or iPSCs (40–42). However, previously, it was difficult to differentiate a sufficient number of chondrocytes with a relatively mature phenotype from ESCs or iPSCs, especially human ESCs or iPSCs. We have recently established a cartilage differentiation system in which iPSCs first differentiate into cells of neural crest character and then into chondrocytes, which enabled us to obtain a large number of chondrocytes with the phenotype of growth plate cartilage chondrocytes. An important aspect of the present study is that this differentiation system can generate a large number of chondrocytes that could share functional properties causing the arthropathy observed in NOMID. This system could thereby be used to screen for novel therapeutic agents.

In conclusion, we showed that SOX9 is overexpressed via the cAMP/PKA/CREB signaling pathway in chondrocytes with disease-causing mutations in NLRP3, and this causes overproduction of ECM independently of the NLRP3 inflammasome. We used iPSC technology to elucidate the role of chondrocytes in the pathophysiology of the human disease NOMID.

ACKNOWLEDGMENTS

We are grateful to K. Hayakawa, M. Fukuta, S. Nagata, and M. Hiraga of Kyoto University for technical assistance and to N. Kambe of Chiba University for critical reading of the manuscript.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Drs. Nishikomori and Toguchida had

full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Yokoyama, Ikeya, Tanaka, Nishikomori, Nakayama, Nakahata, Heike, Toguchida.

Acquisition of data. Yokoyama, Umeda, Nodomi, Horigome, Kusaka, Ohara.

Analysis and interpretation of data. Yokoyama, Umeda, Oda, Nodomi, Nasu, Matsumoto, Izawa, Kusaka, Saito, Yasumi, Nishikomori, Ohara.

ADDITIONAL DISCLOSURES

Author Horigome is an employee of Dainippon Sumitomo Pharma.

REFERENCES

- Kufer TA, Sansonetti PJ. NLR functions beyond pathogen recognition. *Nat Immunol* 2011;12:121–8.
- Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nat Genet* 2001;29:301–5.
- Tanaka N, Izawa K, Saito MK, Sakuma M, Oshima K, Ohara O, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an international multicenter collaborative study. *Arthritis Rheum* 2011;63:3625–32.
- Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. *Am J Hum Genet* 2002;71:198–203.
- Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. *Nat Rev Immunol* 2013;13:397–411.
- Gattorno M, Martini A. Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence [review]. *Arthritis Rheum* 2013;65:1137–47.
- Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. NF- κ B activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. *J Immunol* 2009;183:787–91.
- Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. *Nature* 2006;440:228–32.
- Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. *Lancet* 2004;364:1779–85.
- Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. *N Engl J Med* 2003;348:2583–4.
- Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. *N Engl J Med* 2009;360:2416–25.
- Arostegui JI, Lopez Saldana MD, Pascal M, Clemente D, Aymerich M, Balaguer F, et al. A somatic NLRP3 mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal-onset multisystem inflammatory disease: novel evidence of the role of low-level mosaicism as the pathophysiologic mechanism underlying Mendelian inherited diseases. *Arthritis Rheum* 2010;62:1158–66.
- Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). *Pediatr Radiol* 2007;37:145–52.
- Mackie EJ, Tatarczuch L, Mirams M. The skeleton: a multi-functional complex organ. The growth plate chondrocyte and endochondral ossification. *J Endocrinol* 2011;211:109–21.
- Goldring MB, Tsuchimochi K, Ijiri K. The control of chondrogenesis. *J Cell Biochem* 2006;97:33–44.
- Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D, et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. *PLoS One* 2012;7:e35979.
- Tanaka T, Takahashi K, Yamane M, Tomida S, Nakamura S, Oshima K, et al. Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. *Blood* 2012;120:1299–308.
- Umeda K, Zhao J, Simmons P, Stanley E, Elefanty A, Nakayama N. Human chondrogenic paraxial mesoderm, directed specification and prospective isolation from pluripotent stem cells. *Sci Rep* 2012;2:455.
- Nasu A, Ikeya M, Yamamoto T, Watanabe A, Jin Y, Matsumoto Y, et al. Genetically matched human iPSC cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin. *PLoS One* 2013;8:e53771.
- Sakai H, Okafuji I, Nishikomori R, Abe J, Izawa K, Kambe N, et al. The CD40-CD40L axis and IFN- γ play critical roles in Langerhans giant cell formation. *Int Immunol* 2012;24:5–15.
- Aoyama T, Okamoto T, Nagayama S, Nishijo K, Ishibe T, Yasura K, et al. Methylation in the core-promoter region of the chondro-modulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3. *J Biol Chem* 2004;279:28789–97.
- Ushita M, Saito T, Ikeda T, Yano F, Higashikawa A, Ogata N, et al. Transcriptional induction of SOX9 by NF- κ B family member RelA in chondrogenic cells. *Osteoarthritis Cartilage* 2009;17:1065–75.
- Kajita Y, Kato T Jr, Tamaki S, Furu M, Takahashi R, Nagayama S, et al. The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1). *PLoS One* 2013;8:e49709.
- Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. *Nucleic Acids Res* 2004;32:D91–4.
- Saito M, Fujisawa A, Nishikomori R, Kambe N, Nakata-Hizume M, Yoshimoto M, et al. Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndrome. *Arthritis Rheum* 2005;52:3579–85.
- Saito M, Nishikomori R, Kambe N, Fujisawa A, Tanizaki H, Takeichi K, et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. *Blood* 2008;111:2132–41.
- Aksentijevich I, Nowak M, Maller M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. *Arthritis Rheum* 2002;46:3340–8.
- Akiyama H, Lefebvre V. Unraveling the transcriptional regulatory machinery in chondrogenesis. *J Bone Miner Metab* 2011;29:390–5.
- Kim Y, Murao H, Yamamoto K, Deng JM, Behringer RR, Nakamura T, et al. Generation of transgenic mice for conditional overexpression of Sox9. *J Bone Miner Metab* 2011;29:123–9.
- Cucchiari M, Orth P, Madry H. Direct rAAV SOX9 administration for durable articular cartilage repair with delayed terminal differentiation and hypertrophy in vivo. *J Mol Med (Berlin)* 2013;91:625–36.
- Cucchiari M, Thurn T, Weimer A, Kohn D, Terwilliger EF, Madry H. Restoration of the extracellular matrix in human

- osteoarthritic articular cartilage by overexpression of the transcription factor SOX9. *Arthritis Rheum* 2007;56:158–67.
32. Tew SR, Li Y, Pothacharoen P, Tweats LM, Hawkins RE, Hardingham TE. Retroviral transduction with SOX9 enhances re-expression of the chondrocyte phenotype in passaged osteoarthritic human articular chondrocytes. *Osteoarthritis Cartilage* 2005;13:80–9.
 33. Carroll SH, Ravid K. Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors. *Expert Rev Mol Med* 2013;15:e1.
 34. Huang W, Zhou X, Lefebvre V, de Crombrughe B. Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to transactivate a Col2a1 chondrocyte-specific enhancer. *Mol Cell Biol* 2000;20:4149–58.
 35. Tsuda M, Takahashi S, Takahashi Y, Asahara H. Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9. *J Biol Chem* 2003;278:27224–9.
 36. Yoon YM, Oh CD, Kang SS, Chun JS. Protein kinase A regulates chondrogenesis of mesenchymal cells at the post-precartilage condensation stage via protein kinase C- α signaling. *J Bone Miner Res* 2000;15:2197–205.
 37. Almeida MQ, Tsang KM, Cheadle C, Watkins T, Grivel JC, Nesterova M, et al. Protein kinase A regulates caspase-1 via Ets-1 in bone stromal cell-derived lesions: a link between cyclic AMP and pro-inflammatory pathways in osteoblast progenitors. *Hum Mol Genet* 2011;20:165–75.
 38. Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB, et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca^{2+} and cAMP. *Nature* 2012;492:123–7.
 39. Rossol M, Pierer M, Raulien N, Quandt D, Meusch U, Rothe K, et al. Extracellular Ca^{2+} is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. *Nat Commun* 2012;3:1329.
 40. Barberi T, Willis LM, Socci ND, Studer L. Derivation of multipotent mesenchymal precursors from human embryonic stem cells. *PLoS Med* 2005;2:e161.
 41. Kawaguchi J, Mee PJ, Smith AG. Osteogenic and chondrogenic differentiation of embryonic stem cells in response to specific growth factors. *Bone* 2005;36:758–69.
 42. Zur Nieden NI, Kempka G, Rancourt DE, Ahr HJ. Induction of chondro-, osteo- and adipogenesis in embryonic stem cells by bone morphogenetic protein-2: effect of cofactors on differentiating lineages. *BMC Dev Biol* 2005;5:1.